Circadian Control of Mismatch Repair: A Temporal Gatekeeper Preventing Microsatellite Instability and Field Cancerization in the Aging Colon

Dr. Leo Kofi· Mar 21, 2026

Mechanism: Age-related circadian disruption reduces BMAL1:CLOCK activity and NAD+ levels, leading to inactive MMR genes and accumulation of DNA replication errors. Readout: Readout: Therapeutic interventions restore circadian rhythm and MMR function, reducing Microsatellite Instability (MSI) and tumor multiplicity, while increasing lifespan.

Circadian Regulation of Mismatch Repair as a Defense Against Age‑Related Colorectal Cancer

Hypothesis – The core circadian BMAL1:CLOCK heterodimer directly drives rhythmic transcription of mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) in colonic epithelial stem cells. Age‑associated dampening of circadian amplitude abolishes this transcriptional oscillation, creating periodic windows of MMR deficiency that allow replication errors to accumulate at microsatellite loci. Over time, these errors generate microsatellite instability (MSI) patches that spread via crypt fission, establishing a field cancerized epithelium predisposed to tumorigenesis.

Mechanistic Rationale

Direct transcriptional control – BMAL1:CLOCK binds E‑box elements in the promoters of MMR genes, a prediction supported by ChIP‑seq data showing circadian occupancy at MLH1 and MSH2 loci in liver (https://pmc.ncbi.nlm.nih.gov/articles/PMC10939944/). We propose an analogous binding paradigm in colon crypts.
Chromatin gating – CLOCK stabilizes heterochromatin via lamina interactions (https://doi.org/10.1038/s41422-020-0385-7). When CLOCK activity falls, heterochromatin loosens at MMR promoters, making them accessible to repressive complexes (e.g., Polycomb) during the subjective night, thus imposing a repressive rhythm.
Metabolic coupling – Cellular NAD+ levels oscillate with the clock and modulate SIRT1 deacetylase activity, which in turn deacetylates BMAL1 and enhances its transcriptional output. Age‑related NAD+ decline therefore doubly weakens BMAL1:CLOCK–driven MMR expression.
Feedback to genome stability – Loss of MMR increases microsatellite slippage, activating ATR‑CHK1 signaling. Notably, CRY1 mediates ATR/CHK1 activation in a circadian manner (https://pmc.ncbi.nlm.nih.gov/articles/PMC10939944/), creating a potential vicious cycle where MSI further disrupts clock signaling.

Testable Predictions

Prediction 1: In young wild‑type mice, MMR mRNA and protein levels will exhibit ~24‑hour oscillations in isolated colonic crypts, peaking during the active (dark) phase. This rhythm will be absent in Bmal1‑knockout or constant‑light conditions.
Prediction 2: Aged mice (24 mo) subjected to circadian disruption (constant light or shifted feeding) will show loss of MMR rhythm, elevated MSI rates measured by PCR‑based microsatellite panels, and expanded fields of p53‑negative crypts compared with age‑matched controls on regular light‑dark cycles.
Prediction 3: Pharmacological reinforcement of circadian amplitude (e.g., REV‑ERB agonist SR9009) or NAD+ supplementation (NR) in aged, circadian‑disrupted mice will restore MMR oscillation, reduce MSI incidence, and decrease tumor multiplicity in an APC^Min/+ background.
Prediction 4: Human colon biopsies from older donors with low actigraphy‑derived circadian amplitude will display lower MLH1/MSH2 expression and higher MSI signatures than donors with robust rhythms, after adjusting for inflammation and medication.

Experimental Approach

In vivo: Use PER2::LUC reporter mice to monitor clock function alongside colonic crypt isolation at 4‑hour intervals over two days. Quantify Mrm transcripts by RT‑qPCR and protein by Western blot or immunofluorescence.
MSI assay: Amplify five mononucleotide repeats (BAT‑25, BAT‑26, NR‑21, NR‑24, NR‑27) from microdissected crypts; calculate instability index.
Intervention: Treat cohorts with SR9009 (100 mg/kg i.p. daily) or NR (400 mg/kg diet) for 8 weeks; assess clock amplitude (body temperature rhythm), MMR expression, MSI, and tumor load.
Human validation: Correlate wrist‑actigraphy–derived interdaily stability with mucosal MLH1/IHC and MSI‑seq from colonoscopy biopsies (n ≥ 60 per age stratum).

Falsifiability

If MMR expression proves arrhythmic in young wild‑type crypts, or if restoring circadian rhythms fails to rescue MSI and tumor propensity despite confirmed clock reactivation, the hypothesis would be refuted. Conversely, confirming rhythmic MMR control and its protective effect would position the circadian system as a upstream, tunable firewall against the predominant MMR‑defective pathway of sporadic colorectal cancer.

Broader Implication

Establishing a circadian‑MMR axis would chronobiologize the classic “mutator phenotype” hypothesis, suggesting that timing‑based interventions (chronotherapy, timed nutrition, clock‑enhancing compounds) could prevent field cancerization by preserving the temporal fidelity of DNA repair.

Circadian Regulation of Mismatch Repair as a Defense Against Age‑Related Colorectal Cancer

Mechanistic Rationale

Direct transcriptional control – BMAL1:CLOCK binds E‑box elements in the promoters of MMR genes, a prediction supported by ChIP‑seq data showing circadian occupancy at MLH1 and MSH2 loci in liver (https://pmc.ncbi.nlm.nih.gov/articles/PMC10939944/). We propose an analogous binding paradigm in colon crypts.

Chromatin gating – CLOCK stabilizes heterochromatin via lamina interactions (https://doi.org/10.1038/s41422-020-0385-7). When CLOCK activity falls, heterochromatin loosens at MMR promoters, making them accessible to repressive complexes (e.g., Polycomb) during the subjective night, thus imposing a repressive rhythm.

Metabolic coupling – Cellular NAD+ levels oscillate with the clock and modulate SIRT1 deacetylase activity, which in turn deacetylates BMAL1 and enhances its transcriptional output. Age‑related NAD+ decline therefore doubly weakens BMAL1:CLOCK–driven MMR expression.

Feedback to genome stability – Loss of MMR increases microsatellite slippage, activating ATR‑CHK1 signaling. Notably, CRY1 mediates ATR/CHK1 activation in a circadian manner (https://pmc.ncbi.nlm.nih.gov/articles/PMC10939944/), creating a potential vicious cycle where MSI further disrupts clock signaling.

Testable Predictions

Prediction 1: In young wild‑type mice, MMR mRNA and protein levels will exhibit ~24‑hour oscillations in isolated colonic crypts, peaking during the active (dark) phase. This rhythm will be absent in Bmal1‑knockout or constant‑light conditions.

Prediction 2: Aged mice (24 mo) subjected to circadian disruption (constant light or shifted feeding) will show loss of MMR rhythm, elevated MSI rates measured by PCR‑based microsatellite panels, and expanded fields of p53‑negative crypts compared with age‑matched controls on regular light‑dark cycles.

Prediction 3: Pharmacological reinforcement of circadian amplitude (e.g., REV‑ERB agonist SR9009) or NAD+ supplementation (NR) in aged, circadian‑disrupted mice will restore MMR oscillation, reduce MSI incidence, and decrease tumor multiplicity in an APC^Min/+ background.

Prediction 4: Human colon biopsies from older donors with low actigraphy‑derived circadian amplitude will display lower MLH1/MSH2 expression and higher MSI signatures than donors with robust rhythms, after adjusting for inflammation and medication.

Experimental Approach

In vivo: Use PER2::LUC reporter mice to monitor clock function alongside colonic crypt isolation at 4‑hour intervals over two days. Quantify Mrm transcripts by RT‑qPCR and protein by Western blot or immunofluorescence.

MSI assay: Amplify five mononucleotide repeats (BAT‑25, BAT‑26, NR‑21, NR‑24, NR‑27) from microdissected crypts; calculate instability index.

Intervention: Treat cohorts with SR9009 (100 mg/kg i.p. daily) or NR (400 mg/kg diet) for 8 weeks; assess clock amplitude (body temperature rhythm), MMR expression, MSI, and tumor load.

Human validation: Correlate wrist‑actigraphy–derived interdaily stability with mucosal MLH1/IHC and MSI‑seq from colonoscopy biopsies (n ≥ 60 per age stratum).

Falsifiability